Latest Media Releases

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

SUDA Pharmaceuticals appoints new cell and gene therapy manufacturing expert (ASX:SUD)

Dr Sandhya Buchanan joins SUDA to lead the technology transfer, manufacturing, and quality efforts for its newly acquired invariant Natural Killer T (iNKT) cell therapy platform. Dr Buchanan has ...read more

SUDA Pharmaceuticals - Quarterly Appendix 4C and Activities Report (ASX:SUD)

SUDA Pharmaceuticals Ltd (ASX: SUD), a biotechnology company focused on developing therapies to treat cancer and conditions that affect the central nervous system, today released its Appendix 4C for...read more

Sequoia Financial Group - Application for quotation of securities (ASX:SEQ)

To view the Application for quotation of +securities, download the attached PDF.

Sequoia Financial Group - Notification of cessation of securities (ASX:SEQ)

To view the Notification of cessation of +securities, download the attached PDF.

Sequoia Financial Group - Proposed issue of securities (ASX:SEQ)

To view the Proposed issue of securities, download the attached PDF.

Sequoia Financial Group launches Sequoia Family Office (ASX:SEQ)

Sequoia Financial Group Limited (ASX: SEQ or the Company) is pleased to announce the launch of Sequoia Family Office. Continuing the successful expansion of our Wealth Management business, we are...read more

Sequoia Financial Group - Final Share Buy Back Notice (ASX:SEQ)

Sequoia Financial Group Ltd (Sequoia or the Company) refers to the on-market buy back announced to the ASX on 15 June 2020 (the Buy Back). The Buy Back ended on 30 June 2021 and the Company did not ...read more

SUDA Pharmaceuticals Placement Raises $3.65m (ASX:SUD)

SUDA Pharmaceuticals Ltd (ASX: SUD) is pleased to announce that the Company has received firm commitments for a capital raising by placing up to 96,163,997 ordinary shares to institutional and sophi...read more

SUDA Pharmaceuticals - Proposed issue of securities (ASX:SUD)

To view the Proposed issue of securities, download the attached PDF.

SUDA Pharmaceuticals - Disclosure Document Prospectus $3.65m (ASX:SUD)

To view the prospectus, download the attached PDF.

Sequoia Financial Group - Change in substantial holding (ASX:SEQ)

To view the Notice of change of interest of substantial holder, download the attached PDF.

SUDA Pharmaceuticals - Investor Webinar (ASX:SUD)

SUDA Pharmaceuticals Ltd (ASX: SUD) is pleased to invite shareholders and interested parties to an investor webinar and Q&A hosted by CEO & Managing Director Dr Michael Baker. The webinar...read more

SUDA Pharmaceuticals - Investor Presentation incorporating iNKT Cell Platform (ASX:SUD)

To view the presentation, download the attached PDF.

SUDA Pharmaceuticals Licenses a Novel iNKT Cell Therapy Platform (ASX:SUD)

SUDA Pharmaceuticals Ltd (ASX: SUD), today announces that it has signed a global, exclusive Licence Agreement with Imperial College London for a novel invariant Natural Killer T (iNKT) cell therapy ...read more

SUDA Pharmaceuticals - Trading Halt (ASX:SUD)

The securities of Suda Pharmaceuticals Ltd (‘SUD’) will be placed in trading halt at the request of SUD, pending it releasing an announcement. Unless ASX decides otherwise, the securitie...read more

Viewing: 1 - 15 of 200 Previous | Next